Capecitabine and Oxaliplatin for Advanced Biliary System Cancer
Author Information
Author(s): Nehls O, Oettle H, Hartmann J T, Hofheinz R-D, Hass H G, Horger M S, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B
Primary Institution: University Hospital, Tübingen, Germany
Hypothesis
Is the CAPOX regimen an effective treatment for advanced biliary system adenocarcinomas?
Conclusion
The CAPOX regimen is a well-tolerated and active treatment option for advanced extrahepatic and gallbladder cancers, but less effective for intrahepatic cholangiocarcinoma.
Supporting Evidence
- The response rate in patients with gallbladder or extrahepatic cholangiocarcinoma was 27%.
- Median survival for gallbladder or extrahepatic cholangiocarcinoma patients was 12.8 months.
- Patients with intrahepatic cholangiocarcinoma had a median survival of only 5.2 months.
- Peripheral sensory neuropathy was the most common severe side effect.
Takeaway
Doctors tested a new medicine combination on patients with a type of cancer in the bile system, and it worked better for some patients than others.
Methodology
Patients received oxaliplatin and capecitabine in a structured treatment plan, and their responses were evaluated based on standard criteria.
Potential Biases
Potential selection bias due to non-randomized patient grouping.
Limitations
The study was limited by its small sample size and the non-randomized design.
Participant Demographics
The study included 66 patients, with a median age of 61 years, consisting of 27 men and 39 women.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI, 10.0–15.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website